Valuations Not In Favour Right Now, Says Ajay Tyagi Of UTI AMC
Indian stock market rose 20% in 2023, ending with gains for the record eighth straight year but valuations still remain a concern.
Despite all the segments in the market doing well, large caps continue to be cheaper and small caps are expensive, which is raising concerns, said Ajay Tyagi, head of equities at UTI Asset Management Co.
"We were used to listening to hire for longer," Tyagi told NDTV Profit. "Despite all of this, the year is ending on a very solid note. The only piece of caution here for all investors is that valuations clearly are not in our favor right now."
Though large caps can't be termed as favorably placed—due to their longer-term valuation averages—they are still relatively more attractive than mid and small-caps, he said.
Among possible risks, geopolitics could be a key factor influencing many elements, according to Tyagi. If things move towards the worse, it could impact the cost of food in India and at the same time impact the inflow on income.
The other important factor that could impact the markets would be if the current government does not come back to power, he said. The markets will take a few months to come back to normal if such a situation arises, he said.
However, looking at India's growth these risks will not have a long-term effect and will only be limited to the small-term impacts, Tyagi said.
He leans towards private banks as they will be runners in the coming year, according to him. The second choice is consumer staples and durables. Despite being negatively impacted on account of weakness in rural India, consumer staples "should also see some bit of strength in the coming quarters", he said.
Watch the full conversation here:
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.